Radioimmunoscintigraphy with¹¹¹Indium Labeled Cyt-356 for the Detection of Occult Prostate Cancer Recurrence

A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts

“…Of those used to target CaP, only the Mab 7E11-C5 which is reactive with prostate speci®c membrane (PSMA) showed signi®-cant promise. 1 Nevertheless, CaP remains a theoretically attractive target for in vivo antibody applications because: (a) unlike nearly all other tumors, the targeted antigen does not need to be tumor restricted; expression on normal and malignant prostatic cells is not a signi®cant limitation; (b) if targeting follows a radical prostatectomy there are no normal prostate epithelial cells remaining; (c) the presence of micrometastatic disease post surgery is indicated months to years prior to clinical symptoms using ultra-sensitive prostate speci®c antigen (PSA) assays thus providing unique opportunities for early intervention; and (d) upon therapeutic intervention, the monitoring of PSA levels provides a sense of ef®cacy and duration of response. For these reasons the generation of Mabs suitable for in vivo targeting of CaP is desirable.…”

Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

“…15 In a recent study, of 23 patients with postoperative biochemical failure, 16 patients (70%) with a negative capromab pendetide scan achieved a durable complete response after salvage radiation therapy, with a decrease in serum PSA Յ 0.3 ng/mL for at least 6 months. 11,12 Only 2 of 9 men (22%) with a positive scan beyond the prostatic fossa achieved a durable complete response. 11,12 In our study group, external beam therapy given to patients with localized uptake (prostatic fossa only) on the capromab pendetide scan was associated with an initial 86% biochemical success rate.…”

“…11,12 Only 2 of 9 men (22%) with a positive scan beyond the prostatic fossa achieved a durable complete response. 11,12 In our study group, external beam therapy given to patients with localized uptake (prostatic fossa only) on the capromab pendetide scan was associated with an initial 86% biochemical success rate. The follow-up (mean, 19.3 months), however, was too short for a meaningful conclusion, given the slow and heterogeneous progression of prostate carcinoma.…”

“…The capromab pendetide scan has been shown to detect metastatic lesions as small as 5 mm and, hence, is associated with greater sensitivity for the detection of recurrent prostate carcinoma. 9,10 The sensitivity, specificity, and overall accuracy of this radionuclide scan have been reported at 62%, 72%, and 88%, respectively, in early analyses 11 and at 75%, 86%, and 81%, respectively, in more recent studies. [12][13][14] Earlier capromab pendetide studies of patients with biochemical recurrence after prostate extirpation were performed in men with high serum PSA levels (average, 28.7 ng/mL; median, 13.8 ng/mL) 15 and demonstrated that, whereas 3 of 48 patients (6%) had local prostatic fossa uptake of capromab, 35 of 48 patients (73%) had evidence of antibody uptake beyond the prostatic fossa.…”

Prostate Specific Membrane Antigen as Biomarker and Therapeutic Target for Prostate Cancer

“…It also affects neighboring cells with a heterogeneous antigen expression or insufficient vascularization, which is so called "bystander effect" (Rzeszowska-Wolny et al, 2009). An initial immunoscintigraphic approach targeting PSMA was done with the 111 Indium ( 111 In) labeled anti-PSMA monoclonal antibody 7E11 (Capromab Pendetide (Prosta Scint®), Cytogen, Philadelphia, PA) (Kahn et al, 1994;Sodee et al, 1996;Kahn et al, 1998). With this radioimmunoconjugate a higher sensitivity was reached in the imaging of prostate cancer soft tissue metastases compared to Computed Tomography (CT) or Magnetic Resonance Tomography (MRT) .…”